RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Search
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Rare Diseases: Rare but not alone
We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
Health Equity: No distance is too far
India is hosting the G20 summit. The leading theme of the G20 summit emphasizes health equity and sustainability as part of the agenda. How we provide access to healthcare for rural areas in India.
Heart Diseases in humans and animals
Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
GastroGard the first imported equine drug in China
GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
trust-through-transparency
Transparency is an essential cornerstone of trust in the healthcare industry
World Veterinary Day aspects veterinary profession
• World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.
Boehringer Ingelheim China for a green future
Boehringer Ingelheim China for a green future: China employees were collecting trash on Nanhui Zui Beach for a greener future
Circular economy
Boehringer Ingelheim strives to use resources for as long as possible, process them for reuse or recycle them.
Is artificial intelligence the future of farming?
Odile Bain Memorial Prize 2021
Brilliant early-career scientists in parasitology recognized
Partnering-with-google-in-quantum-computing
New cooperation with Google explores the potentials of quantum computing for pharma R&D.
Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Experts in microbial technology | Bioxcellence | Boehringer Ingelheim
Meet one BioXcellence expert in microbial development and manufacturing. Explore our broad commercial experience and development competence.
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
Angels Initiative in South Africa
Dr Stacey Rossouw explains how the Angels initiative is making a difference in South Africa and optimizing stroke care
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
World water day 2019
Boehringer Ingelheim started a social project in Mexico to preserve the aquifer and to ensure the water supply for dog shelters. Rainwater collector will save 180,000 liters of rainwater every year.
Positive-CHMP-opinion-for-dabigatran-in-children
Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children